Skip to content
Biophytis
LIVE HEALTHIER LONGER
Biophytis
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN

APRIL 27, 2021

Biophytis – Convening of Another Combined General Meeting at a Later Date

Read the press release

Partager cet article
Share on LinkedInShare on LinkedIn Share on XShare on X Share on FacebookShare on Facebook Pin itShare on Pinterest Share on WhatsAppShare on WhatsApp

Post navigation

PreviousPrevious post:APRIL 26, 2021NextNext post:APRIL 29, 2021
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
BIOPHYTIS
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101 (20-hydroxyecdysone)
    • Posters & Publications
    • Macuneos (BIO201)
    • Posters & Publications
  • Investors
    • Financial Calendar
    • AMF Regulated Information
  • Pipeline
    • Key programs milestones
    • COVID-19: COVA clinical program
    • Sarcopenia: SARA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Contact
    • Contact Information
    • Legal information
© Biophytis 2006-2025 - Mentions Légales
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
Footer Colonne 1 - Anglais
Go to Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok